Lezyncet-M Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, indicated for the management of allergic conditions such as allergic rhinitis and chronic idiopathic urticaria. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, nasal congestion, itching, and rhinorrhea. Montelukast, a leukotriene receptor antagonist, blocks leukotriene D4 at the cysteinyl leukotriene receptor, mitigating airway inflammation and bronchoconstriction commonly associated with allergic asthma and rhinitis. The synergistic action of these agents provides comprehensive relief from nasal and ocular allergy symptoms while improving respiratory function. Lezyncet-M is generally well-tolerated; common adverse effects may include headache, fatigue, dry mouth, and gastrointestinal disturbances. It is contraindicated in patients with known hypersensitivity to either component. Caution is advised in patients with hepatic or renal impairment, and dosage adjustments may be necessary. The tablet should be administered orally once daily, preferably in the evening, with or without food. Lezyncet-M offers an effective therapeutic option for patients requiring dual antihistaminic and anti-leukotriene therapy to control allergic manifestations and improve quality of life.